Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
William W. Busse(University of Wisconsin–Madison), Ian Pavord(Oxford BioMedica (United Kingdom)), Nadia Daizadeh, Sally E. Wenzel(National Jewish Health), Thomas B. Casale(University of South Florida), Sivan Harel, Neil M.H. Graham(UK Dementia Research Institute), J. Mark FitzGerald, Megan S. Rice(Children's Medical Research Institute), Paul J. Rowe(Sanofi (United States)), Naimish Patel(Sanofi (United States)), Yamo Deniz(Regeneron (United States)), Thomas G. O’Riordan(Trinity College Dublin)
Cited by 144
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k